This announcement is a separate document:
君实生物自愿披露关于特瑞普利单抗一线治疗黑色素瘤的新适应症上市申请获得受理的公告
Junshi Bio voluntarily disclosed a public announcement regarding the acceptance of its application for a new indication for Trelagliptin single antibody first-line treatment of melanoma.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.